Fertility preservation: Difference between revisions
→Fertility preservation for people who were assigned female at birth
imported>TXJ |
imported>TXJ |
||
| Line 14: | Line 14: | ||
[[Masculinizing hormone therapy]] decreases ovulation and stops menstrual bleeding. However, people on masculinizing HRT may still become pregnant.<ref>{{cite journal | author = Krempasky C, Harris M, Abern L, Grimstad F | year = 2020 | title = Contraception across the transmasculine spectrum | url = https://www.ajog.org/article/S0002-9378(19)30955-X/fulltext | journal = The American Journal of Obstetrics and Gynecology| volume = 222 | issue = 2| pages = 134–143 | doi = 10.1016/j.ajog.2019.07.043 | pmid = 31394072 }}</ref> | [[Masculinizing hormone therapy]] decreases ovulation and stops menstrual bleeding. However, people on masculinizing HRT may still become pregnant.<ref>{{cite journal | author = Krempasky C, Harris M, Abern L, Grimstad F | year = 2020 | title = Contraception across the transmasculine spectrum | url = https://www.ajog.org/article/S0002-9378(19)30955-X/fulltext | journal = The American Journal of Obstetrics and Gynecology| volume = 222 | issue = 2| pages = 134–143 | doi = 10.1016/j.ajog.2019.07.043 | pmid = 31394072 }}</ref> | ||
In patients who have at least begun puberty and who still have their ovaries, oocytes (egg cells) can be cryopreserved for use at a later time. This process can take two or three weeks and requires multiple injections of synthetic hormones which induce oocyte production. During this process, the ovarian cycle is monitored by blood tests and ultrasounds, and eventually the mature oocytes are collected while the patient is sedated. This procedure can be done even if the patient has been on testosterone, but it requires quitting testosterone for a while.<ref name="BlakemoreQuinn2019">{{cite journal|last1=Blakemore|first1=Jennifer K.|last2=Quinn|first2=Gwendolyn P.|last3=Fino|first3=M. Elizabeth|title=A Discussion of Options, Outcomes, and Future Recommendations for Fertility Preservation for Transmasculine Individuals|journal=Urologic Clinics of North America|volume=46|issue=4|year=2019|pages=495–503|issn=00940143|doi=10.1016/j.ucl.2019.07.014}}</ref><ref name="Smith2019" /> | In patients who have at least begun puberty and who still have their ovaries, oocytes (egg cells) can be cryopreserved for use at a later time. This process can take two or three weeks and requires multiple injections of synthetic hormones which induce oocyte production. During this process, the ovarian cycle is monitored by blood tests and ultrasounds, and eventually the mature oocytes are collected while the patient is sedated. This procedure can be done even if the patient has been on testosterone, but it requires quitting testosterone for a while, at least until menstruation resumes, which may cause [[dysphoria]].<ref name="BlakemoreQuinn2019">{{cite journal|last1=Blakemore|first1=Jennifer K.|last2=Quinn|first2=Gwendolyn P.|last3=Fino|first3=M. Elizabeth|title=A Discussion of Options, Outcomes, and Future Recommendations for Fertility Preservation for Transmasculine Individuals|journal=Urologic Clinics of North America|volume=46|issue=4|year=2019|pages=495–503|issn=00940143|doi=10.1016/j.ucl.2019.07.014}}</ref><ref name="Smith2019" /> | ||
Another option is to simply cryopreserve a sample of ovarian tissue. It can be done with patients of any age who have undergone or not undergone puberty, and it can be done at the same time as an [[oophorectomy]] (surgical removal of ovaries). However, this is considered experimental.<ref name="BlakemoreQuinn2019" /> | Another option is to simply cryopreserve a sample of ovarian tissue. It can be done with patients of any age who have undergone or not undergone puberty, and it can be done at the same time as an [[oophorectomy]] (surgical removal of ovaries). However, this is considered experimental.<ref name="BlakemoreQuinn2019" /> | ||